HIV medicine
Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study.
M Gartland, X Wang, Q Liao, B Li, F Du, M Krystal, A R Tenorio, A Pierce, J R Castillo-Mancilla
Published: 202510.1111/hiv.70154
Abstract
OBJECTIVES: The gp120-directed attachment inhibitor fostemsavir was effective in people with multidrug-resistant (MDR) HIV-1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and ide…
Preview only. Read the full abstract at the source